These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21299633)

  • 1. Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program.
    Huang PH; Yeung M; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    J Interv Cardiol; 2011 Jun; 24(3):232-40. PubMed ID: 21299633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
    Brilakis ES; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    J Interv Cardiol; 2011 Aug; 24(4):342-50. PubMed ID: 21492221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
    Lee MS; Yang T; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    EuroIntervention; 2011 Jul; 7(3):314-22. PubMed ID: 21729833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center.
    Shammas NW; Shammas GA; Hahn A; Jerin M; Dippel EJ; Winter M
    Cardiovasc Revasc Med; 2009; 10(3):151-5. PubMed ID: 19595395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of drug-eluting stent implantation for patients with multiple coronary chronic total occlusions.
    Zhang J; Han YL; Li Y; Wang SL; Jing QM; Wang XZ; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2010 Apr; 123(7):789-93. PubMed ID: 20497665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry.
    Lasala JM; Cox DA; Dobies D; Muhlestein JB; Katopodis JN; Revtyak G; Baim DS;
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):433-45. PubMed ID: 18814217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.
    Han YL; Zhang J; Li Y; Wang SL; Jing QM; Yi XH; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2009 Mar; 122(6):643-7. PubMed ID: 19323927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
    Lasala JM; Cox DA; Morris DL; Breall JA; Mahoney PD; Horwitz PA; Shaw D; Hood KL; Mandinov L; Dawkins KD
    Am J Cardiol; 2009 Jun; 103(12):1663-71. PubMed ID: 19539073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry.
    Vaquerizo B; Lefèvre T; Darremont O; Silvestri M; Louvard Y; Leymarie JL; Garot P; Routledge H; de Marco F; Unterseeh T; Zwahlen M; Morice MC
    Circulation; 2009 May; 119(17):2349-56. PubMed ID: 19380624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
    Roy P; Bonello L; de Labriolle A; Okabe T; Pinto Slottow TL; Steinberg DH; Torguson R; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2008 Aug; 102(3):292-7. PubMed ID: 18638589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
    Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
    Mahmoudi M; Delhaye C; Wakabayashi K; Ben-Dor I; Gonzalez MA; Maluenda G; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2011 Jun; 107(12):1757-62. PubMed ID: 21497782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-based paclitaxel-eluting stent for treatment of chronic total occlusions of native coronaries: results of a Taxus CTO registry.
    Buellesfeld L; Gerckens U; Mueller R; Schmidt T; Grube E
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):173-7. PubMed ID: 16144017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.